Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials

Khatami, Alireza; Firooz, Alireza; Gorouhi, Farzam; Dowlati, Yahya

doi:10.1016/j.jaad.2007.01.016

Cited by 117 publications

(102 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence to support different treatments is very limited for HIV-negative CL patients (129,145) and is absent for immunocompromised HIV-coinfected patients.…”

Section: And CLmentioning

confidence: 99%

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

et al. 2008

View full text Add to dashboard Cite

SUMMARY To date, most Leishmania and human immunodeficiency virus (HIV) coinfection cases reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of coinfection were identified, of which 90% were from Spain, Italy, France, and Portugal. However, these figures are misleading because they do not account for the large proportion of cases in many African and Asian countries that are missed due to a lack of diagnostic facilities and poor reporting systems. Most cases of coinfection in the Americas are reported in Brazil, where the incidence of leishmaniasis has spread in recent years due to overlap with major areas of HIV transmission. In some areas of Africa, the number of coinfection cases has increased dramatically due to social phenomena such as mass migration and wars. In northwest Ethiopia, up to 30% of all visceral leishmaniasis patients are also infected with HIV. In Asia, coinfections are increasingly being reported in India, which also has the highest global burden of leishmaniasis and a high rate of resistance to antimonial drugs. Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic.

show abstract

“…Evidence to support different treatments is very limited for HIV-negative CL patients (129,145) and is absent for immunocompromised HIV-coinfected patients.…”

Section: And CLmentioning

confidence: 99%

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Azoles, which were initially designed to treat fungal infection, have been used to treat tegumentary leishmaniasis [88]. Some reports demonstrate the efficacy of fluconazole, ketoconazole, and itraconazole to treat leishmaniasis.…”

Section: Alternative Drugsmentioning

confidence: 99%

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

Goto¹,

Lindoso

2010

Expert Review of Anti-infective Therapy

382

388

View full text Add to dashboard Cite

“…If the lesion is not healing after five treatments, it should be re-examined in 1 month, when a decision about switching to systemic treatment should be made. When such injections are preceded by cryotherapy, which involves bleaching of the lesion for !10 s, the result is more efficacious than their individual use [161,162]. The above-mentioned advantages of topical therapy are easily obtained by formulations containing 15% paromomycin, an aminoglycoside antibiotic, with methlybenzethonium in white soft paraffin or urea and white soft paraffin, or with 0.5% gentamicin.…”

Section: Local Treatmentmentioning

confidence: 99%

Leishmaniasis in travelers: A literature review

Mansueto

Seidita

Vitale

et al. 2014

Travel Medicine and Infectious Disease

111

View full text Add to dashboard Cite

Summary Leishmaniasis is a vector-borne protozoan infection whose clinical spectrum ranges from asymptomatic infection to fatal visceral leishmaniasis. Over the last decades, an increase in imported leishmaniasis cases in developed, non-endemic countries, have been pointed-out from a review of the international literature. Among the possible causes are increasing international tourism, influx of immigrants from endemic regions and military operations. The main area for the acquisition of cutaneous leishmaniasis, especially for adventure travelers on long-term trips in highly-endemic forested areas, is represented from South America, whereas popular Mediterranean destinations are emerging as the main areas to acquire visceral variant. Leishmaniasis should be considered in the diagnostic assessment of patients presenting with a compatible clinical syndrome and a history of travel to an endemic area, even if this occurred several months or years before. Adventure travelers, researchers, military personnel, and other groups of travelers likely to be exposed to sand flies in endemic areas, should receive counseling regarding leishmaniasis and appropriate protective measures. ª

show abstract

Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials

Cited by 117 publications

References 75 publications

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

Leishmaniasis in travelers: A literature review

Contact Info

Product

Resources

About